Saudi Arabia is emerging as a major growth market for clinical trials in the Middle East, underpinned by strong funding and rapidly developing infrastructure.

Estimates suggest fragmented technology can raise clinical trial costs by 45%, but a unified approach to clinical data management can enable efficiency.

BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Chiesi said the KalVista deal will bolster Chiesi Global Rare Diseases, it’s business unit marketing therapies in the sector. Credit: Na_Studio/Shutterstock.com. Chiesi has conducted the largest ...

Teva’s Emalex buyout falls under the company's wider strategy of prioritising deals around de-risked, differentiated, late-stage assets.